Feasibility of a Diabetes Self-Management Program With Continuous Glucose Monitoring for Adults With Type 2 Diabetes

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorthwell Health

About this trial

The purpose of this study is to determine if combining a virtual diabetes self-management program (DECIDE®) with continuous glucose monitoring (CGM) is practical and well-received by adults with type 2 diabetes. Twenty participants will attend the 9-week, virtual DECIDE Self-Management Program. They will receive CGM sensors to wear during the 22-week study to track their blood sugar. Participants will complete questionnaires at three time points -- at baseline, 1 week after the DECIDE Program ends, and 3 months after the DECIDE Program ends. They will also complete a blood draw to measure hemoglobin A1C at baseline and 3 months after the intervention ends. Additionally, they will complete a brief interview after the program ends to gather insights into participants' experiences with the program. The study aims to examine whether this integrated approach will be both feasible and acceptable, potentially leading to better diabetes management and improved health outcomes.

Eligibility criteria

Qualifiers

Aged 18 years or older

Diagnosis of type 2 diabetes

Suboptimal hemoglobin A1C (8.0% or greater) based on a laboratory result in the past 3 months

Access to and capability of using a smart cellular device

Disqualifiers

Currently using CGM

Non-English speaking

Unavailable to attend the virtual DECIDE group

Unavailable for follow-up

Trial design

Treatments tested in this trial

  • The DECIDE Self-Management Program
  • Continuous Glucose Monitoring (CGM)

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

Northwell Health

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Albert Einstein College of Medicine

Collaborator